Fig. 3From: Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patientsCirculating tumor DNA (ctDNA) gene mutation profiles in 16 volunteer Fulvestrant users, stratified by PFS lengths, PFS < 6 months (a) and PFS > 6 months (b). Dark red represents the most common mutated genes and dark blue represents the rarest mutations. If the mutated genes appeared at the same frequency, they are ranked in alphabetic orderBack to article page